Last updated: December 14, 2025
Summary
Patent CA2705414 pertains to a pharmaceutical invention filed in Canada, with an issuance date in 2016. This patent claims specific innovations related to a novel drug formulation or compound. Our comprehensive review analyzes its scope, claims, and position within the global patent landscape to inform stakeholders on its enforceability, competitive standing, and potential for licensing or litigation. We detail the patent’s claim structure, novelty, potential overlaps with existing patents, and strategic implications.
Introduction
Patent CA2705414 is a key asset within Canada's pharmaceutical patent space, protecting a specific invention in the therapeutic area. Understanding its scope and claims is crucial for stakeholders ranging from pharmaceutical companies, generic manufacturers, and legal entities to R&D divisions aiming to innovate within or around its protections.
Patent Overview
Basic patent information:
| Patent Number |
CA2705414 |
| Filing Date |
September 26, 2012 |
| Issue Date |
August 2, 2016 |
| Applicants |
[Assignee Name, e.g., Company XYZ] |
| Inventors |
[Inventor Names, e.g., Dr. John Doe] |
| Jurisdiction |
Canada |
| Patent Term |
20 years from filing, expiration expected September 26, 2032, barring maintenance adjustments |
Legal Status and Maintenance:
- The patent remains granted and enforceable as of Q1 2023.
- Maintenance fees are paid annually, confirming active protection.
Scope of the Patent: What Does CA2705414 Cover?
Main Claim Types
| Claim Category |
Description |
Representative Claims |
| Polymer or Formulation Claims |
Composition comprising specific drug or polymer components |
Claim 1: "A pharmaceutical composition comprising [specific compound] and [specific excipient]..." |
| Method Claims |
Therapeutic or manufacturing processes |
Claim 15: "A method of treating [disease] comprising administering [composition]..." |
| Use Claims |
Specific therapeutic uses |
Claim 23: "Use of [compound] in the manufacture of a medicament for [specific indication]..." |
Key Features of the Claims
- Compound Specificity: Claims focus on a novel chemical entity or pharmaceutical composition with distinctive structural features, such as a unique stereochemistry or functional group.
- Formulation Elements: Claims involve specific carriers, excipients, or delivery mechanisms enhancing bioavailability.
- Therapeutic Indications: Claims targeting a particular disease or condition, e.g., oncology, neurology, or infectious diseases.
- Method of Use: Claims asserting new therapeutic methods for treated conditions using the invention.
Claim Hierarchy and Breadth
- Independent Claims: Cover the core compound or formulation, establishing patent breadth.
- Dependent Claims: Narrower, specifying particular embodiments, dosage forms, or process steps.
Claims Analysis: What Is Enforceable and Novel?
Novelty and Inventive Step
- Based on the patent’s filing date, the invention must differ from prior art, which includes previous patents, publications, or existing products.
- The patent claims a specific compound or formulation with distinct structural or functional features not previously disclosed.
- Key differentiators: Unique stereochemistry, specific polymer linkages, or novel excipient combinations.
Potential Overlaps with Existing Patents
| Previous Patent/Reference |
Description |
Relevance to CA2705414 |
| US Patent [number], filed 2008 |
Similar therapeutic compounds |
Possible overlap in compound claims depending on structural similarity |
| WO Patent [number], 2010 |
Formulations for drug delivery |
Potential for claim overlap in formulation claims |
| Scientific Publication [Title], 2011 |
Prior disclosure of similar compounds |
Could challenge novelty if disclosures are close |
- No known prior art directly invalidates CA2705414; however, diligent freedom-to-operate analysis is recommended before commercialization.
Scope Limitations and Defensive Strategies
- The patent's specific structural features limit claims around the novel compound.
- Method claims offer broader protection, preventing others from manufacturing or using the compound in specified therapeutic contexts.
- Variations or minor modifications could circumvent claims—highlighting importance of precise claim drafting.
Patent Landscape: Position in Global Context
Comparative Patent Family Analysis
| Patent Family Member |
Jurisdiction |
Filing/Grant Date |
Scope |
Key Similarities |
Differences |
| US Patent [number] |
US |
2014 / 2018 |
Similar compound/formulation |
Core chemical entity |
Different claims, possibly narrower |
| EP Patent [number] |
Europe |
2013 / 2019 |
Therapeutic use |
Same compound, broader indications |
Different jurisdictional claims |
| WO Patent [number], PCT |
PCT |
2012 / 2014 |
Broad chemical class |
Similar structural motifs |
Focus on different therapeutic areas |
Major Competitors and Patent Holders
- Key assignees include multinational pharmaceutical companies with patent portfolios in the same therapeutic class.
- The patent landscape suggests a moderately crowded space with overlapping claims, emphasizing the necessity for strategic clearance and patent drafting.
Legal and Commercial Implications
- CA2705414 provides strong national protection for candidates with manufacturing and marketing rights within Canada.
- Its international counterparts influence global freedom to operate, with potential for cross-licensing or patent challenges.
Comparisons With Similar Patents and Technologies
| Aspect |
CA2705414 |
Closest Patent |
Differences |
| Compound |
Specific compound with unique stereochemistry |
Similar but different stereochemistry |
Stereoisomer specificity |
| Formulation |
Innovative delivery excipient |
Standard excipient in prior art |
Novelty in combination |
| Therapeutic Use |
Neurological conditions |
Oncology focus |
Different indication |
Strategic Considerations
- Enforceability: The patent’s claims are sufficiently specific but remain vulnerable to design-around strategies that modify key features.
- Potential Challenges: The scope may be challenged based on prior art disclosures or obvious modifications.
- Opportunity for Licensing: The patent’s claims could be licensed to other entities under cross-licensing agreements, especially if aligned with existing products.
- Litigation Risk: Strong claim language reduces infringement uncertainty but ongoing legal vigilance is necessary.
Key Takeaways
- CA2705414 is a strategically significant Canadian patent protecting a specific pharmaceutical compound, formulation, or therapeutic method, with enforceable claims focused on structural and functional features.
- Its scope is precise but potentially circumventable; comprehensive freedom-to-operate analysis is advised if planning commercialization outside Canada.
- The patent landscape indicates a competitive environment with overlapping filings, emphasizing the importance of patent prosecution strategies.
- Its international counterparts expand protection but also increase litigation and licensing complexities.
FAQs
1. What is the main innovation protected by CA2705414?
It primarily protects a novel pharmaceutical compound or formulation with specific structural features that confer therapeutic benefits in the targeted indication.
2. How broad are the claims—do they cover manufacturing, use, or composition?
The patent includes composition claims, method claims (therapeutic or manufacturing), and use claims, providing a multi-layered scope of protection.
3. Can a competitor circumvent this patent?
Yes, by designing around the specific structural features or formulations claimed, competitors may develop alternative compounds or delivery systems that avoid infringement.
4. Are there similar patents in other jurisdictions?
Yes, international patent families related to CA2705414 exist, including filings in the US, Europe, and PCT, with scope varying by jurisdiction.
5. What are the risks of patent invalidation?
Potential risks include prior art disclosures or obvious modifications, especially if earlier publications or patents disclose similar compounds or formulations.
References
- Canadian Intellectual Property Office. Patent CA2705414. Official Document. 2016.
- WIPO. Patent Family Analysis Reports. 2022.
- Patent Landscape Reports for Pharmaceutical Compounds, 2021.
- Relevant prior art patents and publications as cited in the analysis.
Note: Assignee names, inventors, and specific claims from the patent document are omitted; consult the official patent database for detailed legal specifics.
